The Stitzel Lab

Researches human pancreatic islet cells and the genetic and environmental bases of type 2 diabetes.

Our Research Focus

The overarching goals of my lab at The Jackson Laboratory (JAX) are to determine how genetic and cellular variation contributes to human islet (dys)function and to identify new genes and pathways that may be therapeutically targeted to prevent, delay, or treat type 2 diabetes (T2D). Since the completion of the Human Genome Project and subsequent international efforts demonstrating non-coding DNA sequence roles in controlling cell fate/function and contributing to disease risk, I have been fascinated by this human genome “dark matter”. My program builds on foundational, first-in-kind integrated genome-wide maps of human islet cis­-regulatory elements (CREs) controlling gene expression I created as a postdoctoral fellow with Dr. Francis Collins at NHGRI (Cell Metabolism, 2010 PMC3026436), which revealed extensive overlap between T2D-associated variants and islet CREs and enabled identification of a generalizable “stretch enhancer” epigenomic signature marking regulatory DNA sequences controlling key cell identity/function genes (PNAS, 2013 PMC3816444). 

Since joining JAX in 2013, my lab has used innovative (epi)genomic and transcriptomic profiling of human islets and islet cell models in National Institutes of Health- and Department of Defense- supported efforts to discover candidate causal DNA sequence variants (T2D SNPs) that alter islet CREs (Diabetes, 2018, PMC6198349) and identify new ‘diabetes genes’ that they target (PNAS, 2017, PMC533855), including the first variant-to-function study of the C2CD4A/B locus (AJHG, 2018, PMC5985342). Recently, we have collaborated with Dr. Ryan Tewhey at JAX using massively parallel reporter assays to comprehensively test T2D SNP effects on steady state and stress-responsive gene expression. (Nature Comms, 2021, PMC6198349). Additionally, my lab was among the first in the world to define the transcriptional repertoire of each islet cell type (Genome Research, 2017, PMC5287227), providing unexpected insights into new role(s) and function(s) of islet alpha, beta, delta, and gamma/PP cell types. In a study supported by a highly competitive American Diabetes Association Pathway to Stop Diabetes Accelerator Award, we have recently profiled >250,000 islet single cell transcriptomes from a 48-donor cohort to discover T2D islet beta cell type-specific defects in gene expression, including multiple genes that cause glucose homeostasis defects when deleted in mice (Nargund, Motakis, in preparation).

Current work in my lab is focused on: 1) understanding the genetic control of islet responses to stressors that contribute to islet failure and diabetes (e.g., inflammation, metabolic stress); 2) targeted variant-to-function analyses to understand how T2D SNPs contribute to (dys)function of islet cell organelles/sub-compartments such as the endoplasmic reticulum (ongoing NIH R01), mitochondria (BioRxiv, 2022, doi: 10.1101/2022.08.02.502357 and subject of a newly-funded NIH R01), and peroxisomes; and 3) leveraging regulatory codes and principles we have decoded from genetic and single cell genomic studies of islets to engineer more robust and resilient primary human islet cells.

Full Scientific Report

Epigenome: a tool to discover islet "molecular switches"

Each and every cell in our body contains about 6 billion nucleotide letters constituting our DNA alphabet (3 billion originate from Mom and Dad each, respectively). Only ~1.5% of these nucleotides encode proteins. The remainder has been referred to as junk DNA or the dark matter of the genome. However, emerging data from the ENCyclopedia Of DNA Elements (ENCODE) Consortium and from independent laboratory studies strongly suggest that a substantial portion of these genomic regions function throughout both development and adulthood as molecular switches called enhancers, which control when, where, and how much gene product is generated.

My current work at The Jackson Laboratory is based on research questions and work that I initiated during my postdoctoral fellowship with Dr. Francis S. Collins at the National Human Genome Research Institute. I co-led an epigenetic study to identify molecular switches in human pancreatic islets that may be associated with T2D. As a result of this work, we produced a reference epigenome map of human pancreatic islets (Stitzel et al., Cell Metabolism, 2010), noting that the overwhelming majority of DNA changes shown to be associated with type 2 diabetes are located within these islet regions (61/86) as are most of those associated with the genetic control of fasting blood sugar (glucose; 14/17 known changes) and proinsulin levels (8/9 known changes; Parker, Stitzel et al., PNAS, 2013).

Which switch(es) control which gene(s)? 

Answering this question will represent an important step toward translating the statistically significant associations observed between certain single nucleotide polymorphisms (SNPs) in each person’s genome and the occurrence of T2D into potential clinical insights. Our epigenomic analyses of pancreatic islets have implicated variation in both islet promoters and enhancers in T2D-related pathophysiology. Promoters are the starting points of gene transcription, making target gene identification of these elements straightforward. Identifying the gene(s) that are targeted by enhancers (and therefore most of the T2D GWAS SNPs) is more challenging. For example, a previous investigation of Polymerase II-mediated intrachromosomal interactions has indicated that enhancers skip the nearest promoter on the linear DNA strand, and instead regulate a more distant promoter, up to 40% of the time (Li et al., Cell 2012). A very recent study suggests that extensive interchromosomal interactions occur in the nucleus (Zhang, Wong, et al. Nature 2013). Therefore, to identify enhancer-enhancer and enhancer-promoter interactions in human islets (and to thus identify putative type 2 diabetogenes), it is necessary to study interactions within and between chromosomes. Toward this end, I am collaborating with Dr. Yijun Ruan, Director of JAX Genomic Sciences, to apply chromatin interaction analysis with paired-end tag sequencing (ChIA-PET) technology in islets to answer this important question.

How do enhancer variants alter enhancer activity and islet gene expression? 

We hypothesize that multiple T2D-related gene variants contribute genetic susceptibility to T2D by altering promoter and/or enhancer activity and gene expression in human pancreatic islets. We are currently exploiting the extensive nucleotide diversity present in human populations to test this hypothesis by analyzing allelic imbalances in either histone modifications that are enriched at these elements or in the mRNA transcripts produced by active islet genes. We count the number of times a particular SNP allele is seen (e.g., 5C vs. 2A in the histone modification or 5G vs. 2A in the messenger RNA in the picture) as a measure of SNP effects on these properties. We have recently applied this approach to demonstrate that certain T2D SNPs in the ARAP1 promoter region are associated with higher promoter activity and increased ARAP1 expression (Kulzer et al., AJHG 2014 in press). We are aggressively analyzing more human islet samples to identify additional variants that alter the activity of enhancers and promoters and to determine how subsequent changes in gene expression may lead to T2D.

Stretch enhancers, cell identity and genome-wide association studies (GWAS)

We have completed chromatin and transcriptome profiling in human islets and have integrated these data with those from nine additional ENCODE cell types. These analyses have revealed that sizes of enhancer chromatin states differ widely within every cell type investigated. Stretch enhancers represent the top 10% of enhancer states and are >3 kb in size. They are tissue-specific and overlap locus control regions (LCRs). These enhancers are associated with robust, cell type-specific gene expression and functions. Moreover, GWAS variants associated with cell type-specific traits are more enriched in stretch enhancers than in typical enhancers. We have extended these analyses to 33 cell types to identify additional stretch enhancers associated with cell type-specific gene expression programs and GWAS traits/diseases. Stretch enhancers are more accurate than smaller enhancers to predict cell type-relatedness. Interestingly, pluripotent cell types have fewer stretch enhancers than differentiated cell types. We propose that expanding enhancer territory and establishing stretch enhancers is a process for differentiating cells to establish their identity, perform specific functions, and avoid exploring extraneous regulatory space.

To further pursue these questions, future work in my lab will include: (1) developing alternative and improved techniques to identify stretch enhancers in additional cell types and (2) implementing methods to create and destroy stretch enhancers and to manipulate stretch enhancer activity. Together, we anticipate that these approaches will allow us to coax pluripotent stem cells to mature toward a specific cell fate (directed differentiation), to convert one cell type to another (trans-differentiation), and to modulate genetic susceptibility to common diseases including T2D.